Stereochemistry-Guided Switch From Irreversible to Slow-Binding Cathepsin L Inhibition
Authors/Creators
Contributors
Project leader (2):
Researcher:
Description
Reduced trajectories (5000 snapshots of each 0.5 µs MD data) of the non-covalent complex formed between the inhibitors (D1, D2, D2-flipped and AMK) and cathepsin L (CatL).
Abstract
Due to its involvement in a range of disease-related processes, such as cancer metastasis, viral entry, and immune dysregulation, cathepsin L (CatL), a lysosomal cysteine protease, has been proposed as an attractive therapeutic target. In this work, we present the design, synthesis, and mechanistic investigation of two epoxy ketone-based dipeptidyl CatL inhibitors (D1 and D2), and two azido-based derivatives (AZA and AMK). From a combination of experimental and computational studies, we have demonstrated the importance of epoxide stereochemistry and azido functionality in determining the mode of inhibition and reactivity. Classical and hybrid QM/MM Molecular dynamics (MD) simulations show that only (R)-epoxide (D1) occupies reactive conformations with respect to the catalytic dyad (Cys25–His163), leading to irreversible covalent inactivation via nucleophilic attack at the epoxide functionality. (S)-Epoxide (D2), on the other hand, occupies non-reactive conformations but can reach a less stable "flipped" conformation suggesting a very slow SN2-type attack at the carbon adjacent to the azido moiety. The substitution of the epoxide with an azidomethyl ketone (AMK) preserved the slow-binding covalent competition, but exploration of the free energy landscape revealed a lower activation barrier, consistent with the retention of activity. Kinetic, mass spectrometry (MS), Saturation Transfer Difference (STD) NMR, and thermal-shift studies support the computational predictions and show how slight modifications to the stereochemistry and the warhead of the inhibitor can tune CatL activity, from fully irreversible to slow-binding reversible inhibition. These results provide a rational framework for designing covalent inhibitors with tunable residence times and dual reactivity toward CatL that are important in cancer progression and in viral processes.
Files
Files
(7.6 GB)
| Name | Size | Download all |
|---|---|---|
|
md5:f233e28809f72e375017415fb72703ec
|
2.9 MB | Download |
|
md5:3d021b23cb9d3f742b0d6693f6b5ab7f
|
2.5 MB | Download |
|
md5:6435a9796e68e8890d1f689102ae523e
|
2.5 MB | Download |
|
md5:348a8ff29b61e7ed3a80ea43444b1ece
|
2.5 MB | Download |
|
md5:e11d5d229e3253d5aaf2312a20186915
|
2.0 GB | Download |
|
md5:5c91686976e26fcfece4e918afc6f3af
|
1.9 GB | Download |
|
md5:9a65c59fc9b4203b0f105558e4604fab
|
1.9 GB | Download |
|
md5:9e63977203fcd51f2f3ffefecccf0fb9
|
1.9 GB | Download |